Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists（2023）
Abstract
The biosimilar landscape continues to evolve, and 2023 will see the launch of several adalimumab biosimilar products, which vary with regard to formulation, concentration, and interchangeability status. Pharmacists are well positioned to educate providers and patients about this landscape and help implement an efficient workflow to support adalimumab biosimilar adoption and use.
MoreTranslated text
Key words
adalimumab, biosimilars, inflammatory conditions, specialty pharmacy, switching
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined